Intuitive Surgical, Inc. $ISRG Shares Purchased by Bank of Nova Scotia

Bank of Nova Scotia raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 618,138 shares of the medical equipment provider’s stock after purchasing an additional 75,579 shares during the period. Bank of Nova Scotia’s holdings in Intuitive Surgical were worth $284,959,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Draper Asset Management LLC boosted its holdings in shares of Intuitive Surgical by 41.9% in the fourth quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock worth $2,848,000 after acquiring an additional 1,485 shares during the period. Deutsche Bank AG raised its stake in shares of Intuitive Surgical by 9.6% during the 4th quarter. Deutsche Bank AG now owns 1,522,191 shares of the medical equipment provider’s stock valued at $862,108,000 after purchasing an additional 132,966 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Intuitive Surgical by 29.3% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 71,077 shares of the medical equipment provider’s stock valued at $40,255,000 after purchasing an additional 16,119 shares during the period. Robinhood Asset Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter worth about $6,478,000. Finally, KBC Group NV lifted its holdings in Intuitive Surgical by 4.7% during the 4th quarter. KBC Group NV now owns 420,593 shares of the medical equipment provider’s stock worth $238,207,000 after purchasing an additional 18,697 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG opened at $332.02 on Friday. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The stock has a 50 day simple moving average of $408.55 and a two-hundred day simple moving average of $460.85. The firm has a market cap of $117.30 billion, a P/E ratio of 38.03, a P/E/G ratio of 2.47 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same period last year, the firm posted $1.81 earnings per share. The business’s revenue was up 18.4% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 8.84 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total value of $169,656.00. Following the transaction, the executive vice president owned 5,720 shares in the company, valued at $2,426,080.80. This trade represents a 6.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the completion of the sale, the senior vice president directly owned 6,463 shares of the company’s stock, valued at $2,718,014.65. This represents a 46.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,169 shares of company stock worth $3,059,135 in the last 90 days. 0.60% of the stock is owned by company insiders.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive outlined its AI-enabled future for surgical care, including a five-layer AI framework and real-time telesurgical collaboration, reinforcing its innovation pipeline and potential to deepen its competitive moat. Intuitive Shares Vision for an AI-Enabled Future of Healthcare
• Positive Sentiment: Analyst coverage continues to view ISRG as an attractive long-term MedTech growth name, citing the expanding robotic surgery ecosystem and innovation pipeline. ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?
• Positive Sentiment: CONMED expanded AirSeal robotic compatibility for the da Vinci 5 hex cannula, which supports broader adoption of Intuitive’s newest system. CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
• Neutral Sentiment: Multiple analyst roundups reiterated that Wall Street generally still rates ISRG favorably, but these reports were largely commentary rather than new fundamental catalysts. Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?
• Neutral Sentiment: Recent coverage also emphasized that Intuitive remains a premium valuation story, with valuation support coming from margins, AI software, and international growth, but with slower U.S. procedure growth creating uncertainty. Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?
• Negative Sentiment: J&J’s entry into U.S. robotic surgery increased concerns that da Vinci’s dominance could face real competition, helping pressure sentiment toward ISRG. J&J enters US robotic surgery market after device gets marketing authorization
• Negative Sentiment: Analysts have also trimmed fair value estimates and growth assumptions, citing slower procedure growth and broader MedTech multiple compression, which reinforces concerns that upside may be more limited near term. Intuitive Surgical (ISRG) Stock Sees Fair Value Cut As Analysts Trim Growth Views

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ISRG shares. The Goldman Sachs Group set a $558.00 target price on Intuitive Surgical in a report on Wednesday, May 27th. Wall Street Zen raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Truist Financial cut their price objective on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Piper Sandler restated an “overweight” rating and issued a $470.00 price objective (down from $580.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. Finally, HSBC reduced their price objective on shares of Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Twenty-one research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $523.46.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.